Compounds derived from 5.6 to difenilfuro 2,3-d pyrimidine as no IP prostanoid Receptor Activators

摘要

Refers to a compound of formula I, where a is o, S, NR5 R5 is H, alkyl, cycloalkyl C1 - C3 - C7 C6, C7, C4 l is cicloalquenilo; C1 - C7 alkane dilaurate, replaced or not; Z is a, B, among others; R7 is H, alkyl C1 - C4; R1 and R2 are each halogeno, cyano, Nitro, c1-c6 alkyl, cycloalkyl C3 - C7, T Rifluorometoxi, among others; and N is 0 OR 1; R IS h, c1-c4 alkyl; R4 is H, ciclopropilo,C1-c4 alkyl. Preferred compounds are: Acid 6 - {[2 - (4-methoxyphenyl) - 6 - fenilfuro [2,3-d] pyrimidin-4-yl] amino hexanoic acid 7}; {- [5 - (4-methoxyphenyl) 6 - fenilfuro [2,3-d] pyrimidin-4-yl] amino} HEPTANOIC ACID 5 - (4-methoxyphenyl) - 6 - (N - phenyl - 3 - [2 - (1h-tetrazol-5-yl) ethoxy] propyl] furo [2,3-d] pyrimidin-2-yl) - Amine; among others. Also referred to as a preparation method and a Pharmaceutical composition.These compounds are useful in the treatment of cardiovascular diseases